<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Fam Pract</journal-id><journal-title>BMC Family Practice</journal-title><issn pub-type="epub">1471-2296</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15353006</article-id><article-id pub-id-type="pmc">PMC518964</article-id><article-id pub-id-type="publisher-id">1471-2296-5-19</article-id><article-id pub-id-type="doi">10.1186/1471-2296-5-19</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Dawson</surname><given-names>Marliese Y</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mdawson@interchange.ubc.ca</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Michalak</surname><given-names>Erin E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>emichala@interchange.ubc.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Waraich</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>waraich@interchange.ubc.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Anderson</surname><given-names>J Ellen</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jeanderson@telus.net</email></contrib><contrib id="A5" corresp="yes" contrib-type="author"><name><surname>Lam</surname><given-names>Raymond W</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>r.lam@ubc.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Clinical Neuroscience, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada V6T 2A1</aff><aff id="I2"><label>2</label>Division of Mental Health Services, Department of Psychiatry, Universityof British Columbia, 2250 Wesbrook Mall, Vancouver, BC, Canada V6T 1W6</aff><aff id="I3"><label>3</label>Family Physician, 6625B Sooke Road, Sooke, BC, Canada V0S 1N0</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>7</day><month>9</month><year>2004</year></pub-date><volume>5</volume><fpage>19</fpage><lpage>19</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2296/5/19"/><history><date date-type="received"><day>7</day><month>4</month><year>2004</year></date><date date-type="accepted"><day>7</day><month>9</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Dawson et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Dawson et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Dawson
               Y
               Marliese
               
               mdawson@interchange.ubc.ca
            </dc:author><dc:title>
            Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis
         </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>BMC Family Practice 5(1): 19-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2296(2004)5:1&#x0003c;19&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2296</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>A primary goal of acute treatment for depression is clinical remission of symptoms. Most meta-analyses of remission rates involve randomized controlled trials (RCTs) using patients from psychiatric settings, but most depressed patients are treated in primary care. The goal of this study was to determine remission rates obtained in RCTs of treatment interventions for Major Depressive Disorder (MDD) conducted in primary care settings.</p></sec><sec sec-type="methods"><title>Methods</title><p>Potentially relevant studies were identified using computerized and manual search strategies up to May 2003. Criteria for inclusion included published RCTs with a clear definition of remission using established outcome measures.</p></sec><sec><title>Results</title><p>A total of 13 studies (N = 3202 patients) meeting inclusion criteria were identified. Overall remission rates for active interventions ranged between 50% and 67%, compared to 32% for pill placebo conditions and 35% for usual care conditions.</p></sec><sec><title>Conclusions</title><p>Remission rates in primary care studies of depression are at least as high as for those in psychiatric settings. It is a realistic goal for family physicians to target remission of symptoms as an optimal outcome for treatment of depression.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Major depressive disorder (MDD) is one of the most common and disabling of medical conditions [<xref ref-type="bibr" rid="B1">1</xref>]. The Canadian Community Health Survey recently reported a one-year prevalence rate of 4.5% for MDD, indicating that over 1.1 million Canadians suffer significant distress and impairment in function due to depression [<xref ref-type="bibr" rid="B2">2</xref>]. The economic costs of depression are estimated at over $5 billion annually [<xref ref-type="bibr" rid="B3">3</xref>]. Depression is currently the fourth-ranked medical condition contributing to global burden of disease, and is estimated to rise to second overall by the year 2010 [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>There are many effective treatments for MDD, including psychotherapy and antidepressants. Traditionally, efficacy in randomized controlled trials (RCTs) for depression has been determined on the basis of score changes in rating scales such as the Hamilton Depression Rating Scale (HDRS) [<xref ref-type="bibr" rid="B5">5</xref>] or the Montgomery-Asberg Depression Rating Scale (MADRS) [<xref ref-type="bibr" rid="B6">6</xref>]. Clinical outcome has been usually assessed by clinical response rates, typically defined as a 50% or greater reduction from baseline scores on these rating scales [<xref ref-type="bibr" rid="B7">7</xref>]. Although obtaining clinical response represents an important therapeutic milestone, it does not necessarily indicate a complete recovery from MDD, since many patients with clinical response will still be left with substantial residual symptoms of depression. Studies have shown that the presence of residual symptoms after an episode of MDD is associated with higher risk of relapse, recurrence, chronicity, suicide, development of cardiovascular disease, and poor quality of life [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Such findings suggest that the goals of acute treatment (approximately the first 8&#x02013;12 weeks or so of treatment) for MDD should be clinical remission, a clinical state distinguished by minimal residual symptoms, rather than just response [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Clinical remission is typically defined as a score within the normal range on a given outcome measure (e.g., 17-item HDRS score of 7 or less; MADRS score of 12 or less; Clinical Global Impression [CGI] [<xref ref-type="bibr" rid="B14">14</xref>] severity score of "Normal, not at all ill"), although there is still some uncertainty as to the validity of these cutoff scores for symptom remission [<xref ref-type="bibr" rid="B15">15</xref>]. The achievement of remission is of considerable clinical importance as it predicts decreased risk of relapse and greater psychosocial functioning than typically observed in patients who have achieved clinical response alone [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Clinical remission is now identified and promoted as a clinical target for successful management of MDD in many clinical practice guidelines [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B21">21</xref>].</p><p>Increasing numbers of treatment studies are now explicitly reporting both clinical response and remission rates in assessment of outcome. A meta-analysis of 8 antidepressant studies of venlafaxine versus selective serotonin reuptake inhibitors [SSRIs] and placebo reported mean remission rates of 45%, 35%, and 25%, respectively [<xref ref-type="bibr" rid="B22">22</xref>]. A subsequent meta-analysis of 32 RCTs comparing venlafaxine, SSRIs and other antidepressants reported a mean overall remission rate of 42% [<xref ref-type="bibr" rid="B23">23</xref>]. Finally, a meta-analysis of 6 RCTs comparing antidepressants and psychotherapy in patients with MDD reported mean remission rates of 46% for each treatment [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>All the studies in these systematic reviews involved patients in psychiatric or mixed settings. However, most people suffering from MDD will be managed in the primary care setting [<xref ref-type="bibr" rid="B25">25</xref>]. Approximately 5% to 10% of all patients consulting a general practitioner have MDD, with prevalence estimates being two to three times higher when other depressive disorders (i.e., minor depression or dysthymia) are included [<xref ref-type="bibr" rid="B26">26</xref>]. It remains unclear whether the remission rates reported in psychiatric settings can be extrapolated to primary care environments, although it is of clinical importance for primary care physicians to know whether obtaining remission is a realistic goal for their patients. There has been a recent surge in studies assessing a variety of treatment interventions for depression in primary care settings, making this an opportune time to perform a meta-analysis to address this question. Hence, the primary objective of this study was to determine remission rates obtained in RCTs of treatment interventions for MDD conducted in primary care settings.</p></sec><sec sec-type="methods"><title>Methods</title><p>Potentially relevant studies were identified using computerized and manual search strategies. The computerized search conducted in June, 2003 included the databases: Medline, Psych Info, Embase, Biosis, Cochrane Database of Systematic Reviews, and Cochrane Controlled Trials Register and Current Controlled Trials (1981&#x02013;May 2003). The search terms used were 'depressive disorder' or 'depression' combined with 'primary care' and 'remission' and/or variants. The bibliographies of relevant articles were also manually searched. Two reviewers (MYD and RWL) collected and independently assessed abstracts for inclusion criteria. Disagreements were resolved with consensus.</p><sec><title>Inclusion criteria</title><p>Studies were included if they were RCTs with original data comparing one or more interventions (e.g., antidepressant vs. cognitive behavioral therapy) and published in English. Only studies of predominantly adult populations, as opposed to exclusively child or elderly patient populations, were included. Although the focus was principally upon patients with MDD (studies primarily dealing with minor depression and dysthymia were excluded), the criteria for a diagnosis of MDD was intentionally broad in order to capture the heterogeneity of the sample and allow the results to be as generalizable as possible. Included studies also had to use a standardized outcome measure (e.g., HDRS, MADRS, Beck Depression Inventory [BDI] [<xref ref-type="bibr" rid="B27">27</xref>]) and provide explicit criteria for remission. While the definition of remission varied among the studies (Table <xref ref-type="table" rid="T1">1</xref>), for the purpose of this meta-analysis we accepted each study's definition of remission, which usually was a score within the normal range on the outcome measure.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Summary of included studies in meta-analysis of remission rates.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Study</bold></td><td align="center"><bold>Diagnostic Criteria</bold></td><td align="center"><bold>Follow up Period</bold></td><td align="center"><bold>Remission Criteria</bold></td><td align="center"><bold>Total N</bold></td><td align="center"><bold>Intervention</bold></td><td align="center"><bold>Intervention Remission Rate</bold></td><td align="center"><bold>Remission %</bold></td></tr></thead><tbody><tr><td align="left" colspan="8"><bold>Psychological Intervention Only</bold></td></tr><tr><td align="left">Dowrick et al., 2000 [31]</td><td align="left">DSM-IV criteria for MDD or Adjustment Disorder</td><td align="center">6 months</td><td align="left">No MDD detected by SCAN interview</td><td align="center">425</td><td align="left">&#x02022; PST<break/>&#x02022; Usual Care<break/>&#x02022;Prevention course</td><td align="left">&#x02022; 58/128<break/>&#x02022; 76/189<break/>&#x02022; 44/108</td><td align="left">&#x02022; 45<break/>&#x02022; 38<break/>&#x02022; 41</td></tr><tr><td align="left" colspan="8"><bold>Antidepressant Intervention Only</bold></td></tr><tr><td align="left">Benkert et al., 2000 [32]</td><td align="left">DSM-IV criteria for MDD and HDRS &#x02265; 18</td><td align="center">6 weeks</td><td align="left">HDRS &#x02264; 7</td><td align="center">275</td><td align="left">&#x02022; Mirtazapine<break/>&#x02022; Paroxetine</td><td align="left">&#x02022; 52/139<break/>&#x02022; 42/136</td><td align="left">&#x02022; 37<break/>&#x02022; 31</td></tr><tr><td align="left">Patris et al.,1996 [33]</td><td align="left">DSM-IIIR criteria for MDD</td><td align="center">8 weeks</td><td align="left">MADRS &#x02264; 12</td><td align="center">357</td><td align="left">&#x02022; Citalopram<break/>&#x02022; Fluoxetine</td><td align="left">&#x02022; 114/173<break/>&#x02022; 110/184</td><td align="left">&#x02022; 66<break/>&#x02022; 60</td></tr><tr><td align="left">Wade et al., 2002 [34]</td><td align="left">DSM-IV criteria for MDD</td><td align="center">8 weeks</td><td align="left">MADRS &#x02264; 12</td><td align="center">380</td><td align="left">&#x02022; Escitalopram<break/>&#x02022; Placebo</td><td align="left">&#x02022; 92/191<break/>&#x02022; 64/189</td><td align="left">&#x02022; 48<break/>&#x02022; 34</td></tr><tr><td align="left" colspan="8"><bold>Psychological Intervention + Antidepressants</bold></td></tr><tr><td align="left">Chilvers et al., 2001 [35]</td><td align="left">Diagnosed as MDD by GP</td><td align="center">12 months</td><td align="left">RDC &#x0003c;4, BDI &#x0003c;10, or clear documentation in GP notes that patient is well</td><td align="center">103</td><td align="left">Randomised only:<break/>&#x02022; Antidepressant<break/>&#x02022; Counselling</td><td align="left">&#x02022; 39/51<break/>&#x02022; 33/52</td><td align="left">&#x02022; 76<break/>&#x02022; 63</td></tr><tr><td align="left">Mynors-Wallis et al., 1995 [36]</td><td align="left">Diagnosed as MDD by GP</td><td align="center">12 weeks</td><td align="left">HDRS &#x02264; 7 or BDI &#x02264; 8</td><td align="center">91</td><td align="left">&#x02022; PST<break/>&#x02022; Amitriptyline<break/>&#x02022; Placebo</td><td align="left">&#x02022; 18/30<break/>&#x02022; 16/31<break/>&#x02022; 8/30</td><td align="left">&#x02022; 60<break/>&#x02022; 52<break/>&#x02022; 27</td></tr><tr><td align="left">Mynors-Wallis et al., 2000 [37]</td><td align="left">RDC criteria for MDD</td><td align="center">12 months</td><td align="left">HDRS &#x02264; 8</td><td align="center">151</td><td align="left">&#x02022; PST-group<break/>&#x02022;PST-RN<break/>&#x02022; Antidepressant<break/>&#x02022; PST+antidepressant</td><td align="left">&#x02022; 24/39<break/>&#x02022; 23/41<break/>&#x02022; 20/36<break/>&#x02022; 23/35</td><td align="left">&#x02022; 62<break/>&#x02022; 56<break/>&#x02022; 56<break/>&#x02022; 66</td></tr><tr><td align="left">Schulberg et al., 1998 [38]</td><td align="left">DSM-IIIR criteria for MDD</td><td align="center">8 months</td><td align="left">HDRS &#x02264; 7</td><td align="center">184</td><td align="left">&#x02022; IPT<break/>&#x02022; Nortriptyline</td><td align="left">&#x02022; 49/93<break/>&#x02022; 52/91</td><td align="left">&#x02022; 57<break/>&#x02022; 53</td></tr><tr><td align="left">Scott et al., 1992 [39]</td><td align="left">DSM-IIIR criteria for MDD</td><td align="center">4 months</td><td align="left">HDRS &#x02264; 7</td><td align="center">121</td><td align="left">&#x02022; CBT<break/>&#x02022; Counselling<break/>&#x02022; Amitriptyline<break/>&#x02022; Usual care</td><td align="left">&#x02022; 12/30<break/>&#x02022; 22/30<break/>&#x02022; 18/31<break/>&#x02022; 14/30</td><td align="left">&#x02022; 40<break/>&#x02022; 73<break/>&#x02022; 58<break/>&#x02022; 47</td></tr><tr><td align="left" colspan="8"><bold>Program Interventions</bold></td></tr><tr><td align="left">Katon et al.,1999 [40]</td><td align="left">Diagnosed as MDD by GP</td><td align="center">6 months</td><td align="left">Presence of 0 or 1 SCID-assessed symptoms</td><td align="center">228</td><td align="left">&#x02022; Collaborative care<break/>&#x02022; Usual Care</td><td align="left">&#x02022; 50/114<break/>&#x02022; 35/114</td><td align="left">&#x02022; 44<break/>&#x02022; 31</td></tr><tr><td align="left">Katzelnick et al., 2000 [41]</td><td align="left">Diagnosed as MDD by GP and HDRS &#x02265; 15</td><td align="center">12 months</td><td align="left">HDRS &#x02264; 7</td><td align="center">407</td><td align="left">&#x02022; Depression management<break/>&#x02022; Usual care</td><td align="left">&#x02022; 92/218<break/>&#x02022; 49/189</td><td align="left">&#x02022; 42<break/>&#x02022; 26</td></tr><tr><td align="left">Kutcher et al., 2002 [42]</td><td align="left">Diagnosed as MDD by GP</td><td align="center">29 weeks</td><td align="left">8 weeks or longer with HDRS &#x02264; 10</td><td align="center">269</td><td align="left">&#x02022; Sertraline<break/>&#x02022; Sertraline + adherence program</td><td align="left">&#x02022; 84/138<break/>&#x02022; 88/131</td><td align="left">&#x02022; 61<break/>&#x02022; 67</td></tr><tr><td align="left">Rost et al., 2002 [43]</td><td align="left">Diagnosed as MDD by GP</td><td align="center">24 months</td><td align="left">CES-D &#x02264; 16</td><td align="center">211</td><td align="left">&#x02022; Enhanced depression care<break/>&#x02022; Usual care</td><td align="left">&#x02022; 85/115<break/>&#x02022; 39/96</td><td align="left">&#x02022; 74<break/>&#x02022; 41</td></tr></tbody></table><table-wrap-foot><p>(Abbreviations: BDI &#x02013; Beck Depression Inventory, CBT &#x02013; Cognitive Behavioural Therapy, CES-D &#x02013; Centre for Epidemiological Studies &#x02013; Depression Scale, HDRS &#x02013; Hamilton Depression Rating Scale, HSCL-D-20 &#x02013; 20-item Hopkins Symptom Check List, IPT-Interpersonal Psychotherapy, MADRS &#x02013; Montgomery-Asberg Depression Rating Scale, MDD &#x02013; Major Depressive Disorder, PST &#x02013; Problem Solving Therapy, PST-PC &#x02013; Problem Solving Therapy, administered by Primary Care Physician, PST-RN &#x02013; Problem Solving Therapy, administered by Registered Nurse, RDC &#x02013; Research Diagnostic Criteria, SCAN &#x02013; Schedules of Clinical Assessment in Neuropsychiatry, SCID &#x02013; Structured Clinical Interview for DSM-III-R.)</p></table-wrap-foot></table-wrap></sec><sec><title>Data extraction</title><p>Two independent reviewers (MYD and EEM) extracted data from studies using a checklist developed for this study, with disagreements resolved by a third reviewer (RWL). A conservative measure of remission rate was calculated from each study using an intent-to-treat analysis [<xref ref-type="bibr" rid="B28">28</xref>], even if this method was not used in the study. For example, some studies calculated remission rates using only patients who returned for one follow-up visit post-randomization, or who had completed a course of treatment. The denominator used for remission rate was the total number of patients randomized to treatment, whether or not they were counted in the ensuing analysis. The numerator was the number of patients in remission reported in the study, regardless of the denominator used in the study analysis.</p><p>The type of intervention was classified as placebo, "usual care" by clinician (standard treatment by a patient's own physician), psychotherapy treatment only, antidepressant treatment only, psychotherapy plus antidepressant treatment, or program intervention (e.g., collaborative care using other health professionals; educational programs targeted at quality improvement for prescribing practices).</p></sec><sec><title>Statistics</title><p>Each set of rates was pooled based on a Bayesian approach to meta-analysis using the Fastpro software program (version 1.7) by Eddy and Hasselblad. Readers interested in a more detailed discussion of this approach should refer to Eddy et al [<xref ref-type="bibr" rid="B29">29</xref>]. The pooled means and confidence intervals were calculated using Jeffrey's prior and a random effects model.</p></sec></sec><sec><title>Results</title><p>The initial electronic and bibliographic search found 63 articles of which 47 warranted more detailed review based on the published abstract. Of these, 34 articles were excluded due to methodology (not RCTs, 4 studies), lack of remission criteria (18 studies), diagnostic criteria (not MDD, 11 studies) and age criteria (geriatric, 4 studies) (some studies were excluded for multiple reasons, see <xref ref-type="supplementary-material" rid="S1">Additional File 1</xref>). A final count of 13 studies met the full inclusion criteria (Table <xref ref-type="table" rid="T1">1</xref>). In total, 3202 primary care outpatients (75% female, 25% male) were included in the analysis. The mean age of the participants was 32.1 years (range 18&#x02013;73 years). The average length of follow-up was 32 weeks (range 6&#x02013;104 weeks).</p><p>The study interventions and methodologies were too heterogeneous to allow for a meaningful statistical comparison of results between treatments. Figure <xref ref-type="fig" rid="F1">1</xref> shows mean remission rates for specific interventions. Overall remission rates for active interventions, regardless of type, ranged between 50% and 67%, compared to 32% for pill placebo conditions and 35% for usual care conditions. There were a sufficient number of antidepressant arms in the studies to permit the summary of remission rates by duration of follow-up period. For antidepressant studies with follow-up of 6 months or less, mean remission rate was 51.4% (95% C.I., 43.1%&#x02013;59.6%); for antidepressant studies with greater than 6 months of follow-up, mean remission rate was 62.3% (95% C.I., 48.9%&#x02013;74.8%).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Remission rates for specific treatment conditions from randomized controlled trials (RCTs) of interventions for depression in primary care settings. The white lines represent the mean remission rates and the boxes represent the 95% confidence interval. N is the number of treatment arms in the RCTs (Note: Psychotx = Psychotherapy, Antidepr = Antidepressants, pts = patients).</p></caption><graphic xlink:href="1471-2296-5-19-1"/></fig></sec><sec><title>Discussion</title><p>This review of research assessing remission of depressive symptoms in primary care populations identified 13 studies meeting the inclusion criteria. Overall remission rates (regardless of type of intervention but excluding placebo or usual care arms) ranged between 50% and 67%. These rates are equivalent to, or indeed greater than, those reported in meta-analyses of studies examining pharmacological or psychological interventions for depression in psychiatric populations, in which the overall remission rates ranged between 35% and 46% [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. On the one hand, we might have predicted this finding as studies conducted in primary care settings tend to include more patients with mild to moderate depression (although we excluded studies that focused exclusively upon minor depression or dysthymia), whereas patients referred to psychiatric settings are more likely to have moderate to severe depression. Primary care treatment trials also tend to be longer, favouring a higher remission rate; whereas the mean follow-up period of studies included in the current analysis was 9 months, it was only 7 weeks and 10 weeks in the two previous meta-analyses of pharmacological interventions for MDD [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>], and 16 weeks in the meta-analysis of antidepressant versus psychotherapeutic interventions [<xref ref-type="bibr" rid="B24">24</xref>]. Conversely, we might have predicted that we would observe <italic>lower </italic>remission rates in the current meta-analysis as it included a number of studies with more lenient exclusion criteria than typically used in psychiatric clinical trials. In particular, the program intervention studies tend to include more heterogeneous patient populations as they do not routinely exclude patients with psychiatric or medical comorbidities, factors that may lessen the likelihood of obtaining remission of depressive symptoms [<xref ref-type="bibr" rid="B30">30</xref>].</p><p>While it was not within the scope of the current study to compare the effectiveness of different treatment interventions in improving remission rates, we can report on the trends we observed in the data. Antidepressant and psychotherapy interventions delivered in isolation showed similar remission rates (54% for both). Combination antidepressant plus psychotherapy interventions showed somewhat higher rates (67%), although this category included only 1 arm with only 35 patients. Program interventions had a mean remission rate of 50%, and all treatment interventions fared better than either placebo (32%) or usual care (35%).</p><p>The studies identified in our review were quite heterogeneous in nature, ranging from those that looked solely at the effects of a particular pharmacological agent, through to complex program initiatives that incorporated a variety of interventions at different levels of care. This heterogeneity limits our ability to make broad comments about remission rates in primary care, but was not unexpected, as we wanted to capture the diversity of treatment interventions for depression currently being tested in this setting. Other potential limitations of the study include that fact that we only assessed published studies written in English and that we used a conservative measure of remission rate. Finally, we also used the definition of remission as specified by each individual study. While these definitions were similar to those widely used in RCTs conducted in psychiatric settings, and thus are useful for comparison, there is current controversy about depression scales and which cutoff scores indicate true remission of symptoms [<xref ref-type="bibr" rid="B15">15</xref>].</p></sec><sec><title>Conclusions</title><p>This meta-analysis serves to answer an important clinical question about the feasibility of obtaining remission of symptoms of MDD in primary care patients. Our results indicate that this is a realistic goal in this population, although further research is still required to determine whether certain treatment modalities (or combinations of treatment interventions) are superior to others in achieving higher remission rates. Future research should also focus upon developing pragmatic strategies for general practitioners to implement evidence-based guidelines concerning the treatment of depression to clinical remission.</p></sec><sec><title>Authors' contributions</title><p>MYD and EEM conducted the data extraction, wrote the initial draft of the manuscript, interpreted results, and revised the manuscript. PW provided statistical consultation and analysis, and revised the manuscript. JEA interpreted the results and revised the manuscript. RWL conceived the initial idea, developed the method, interpreted results, revised the manuscript, and provided financial resources for the study. All authors read and approved the final manuscript.</p></sec><sec><title>Competing interests</title><p>RWL is on advisory/speaker boards or has received research funds from: AstraZeneca, Biovail, Canadian Network for Mood and Anxiety Treatments, Eli Lilly, GlaxoSmithKline, Janssen-Ortho, Litebook, Inc., Lundbeck, Merck, Organon, Roche, Shire, Servier, and Wyeth.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2296/5/19/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional File 1</title><p>Studies excluded from the review</p></caption><media xlink:href="1471-2296-5-19-S1.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgments</title><p>Dr. Michalak was supported by a Canadian Institutes of Health Research/Wyeth Canada Postdoctoral Fellowship Award.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>SV</given-names></name><name><surname>Lam</surname><given-names>RW</given-names></name></person-group><article-title>Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden</article-title><source>Can J Psychiatry</source><year>2001</year><volume>46 Suppl 1</volume><fpage>13S</fpage><lpage>20S</lpage><pub-id pub-id-type="pmid">11441768</pub-id></citation></ref><ref id="B2"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Statistics Canada</surname><given-names/></name></person-group><article-title>Canadian Community Health Survey: Mental health and well-being.</article-title><source>www statcan ca/Daily/English/030903/d030903a htm, accessed November 9,</source><year>2003</year></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desjardins</surname><given-names>B</given-names></name><name><surname>Laurier</surname><given-names>C</given-names></name></person-group><article-title>The burden of depression in Canada.</article-title><source>Value in Health</source><year>2002</year><volume>5</volume><fpage>229</fpage></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name></person-group><article-title>Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>1498</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">9167458</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(96)07492-2</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>M</given-names></name></person-group><article-title>Development of a rating scale for primary depressive illness.</article-title><source>Br J Soc Clin Psych</source><year>1967</year><volume>6</volume><fpage>278</fpage><lpage>296</lpage></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Asberg</surname><given-names>M</given-names></name></person-group><article-title>A new depression scale designed to be sensitive to change</article-title><source>Br J Psychiatry</source><year>1979</year><volume>134</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">444788</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>E</given-names></name><name><surname>Prien</surname><given-names>RF</given-names></name><name><surname>Jarrett</surname><given-names>RB</given-names></name><name><surname>Keller</surname><given-names>MB</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name><name><surname>Lavori</surname><given-names>PW</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Weissman</surname><given-names>MM</given-names></name></person-group><article-title>Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence</article-title><source>Arch Gen Psychiatry</source><year>1991</year><volume>48</volume><fpage>851</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">1929776</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Judd</surname><given-names>LL</given-names></name><name><surname>Akiskal</surname><given-names>HS</given-names></name><name><surname>Maser</surname><given-names>JD</given-names></name><name><surname>Zeller</surname><given-names>PJ</given-names></name><name><surname>Endicott</surname><given-names>J</given-names></name><name><surname>Coryell</surname><given-names>W</given-names></name><name><surname>Paulus</surname><given-names>MP</given-names></name><name><surname>Kunovac</surname><given-names>JL</given-names></name><name><surname>Leon</surname><given-names>AC</given-names></name><name><surname>Mueller</surname><given-names>TI</given-names></name><name><surname>Rice</surname><given-names>JA</given-names></name><name><surname>Keller</surname><given-names>MB</given-names></name></person-group><article-title>Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse</article-title><source>J Affect Disord</source><year>1998</year><volume>50</volume><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">9858069</pub-id><pub-id pub-id-type="doi">10.1016/S0165-0327(98)00138-4</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Judd</surname><given-names>LL</given-names></name><name><surname>Paulus</surname><given-names>MJ</given-names></name><name><surname>Schettler</surname><given-names>PJ</given-names></name><name><surname>Akiskal</surname><given-names>HS</given-names></name><name><surname>Endicott</surname><given-names>J</given-names></name><name><surname>Leon</surname><given-names>AC</given-names></name><name><surname>Maser</surname><given-names>JD</given-names></name><name><surname>Mueller</surname><given-names>T</given-names></name><name><surname>Solomon</surname><given-names>DA</given-names></name><name><surname>Keller</surname><given-names>MB</given-names></name></person-group><article-title>Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?</article-title><source>Am J Psychiatry</source><year>2000</year><volume>157</volume><fpage>1501</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">10964869</pub-id><pub-id pub-id-type="doi">10.1176/appi.ajp.157.9.1501</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Judd</surname><given-names>LL</given-names></name><name><surname>Akiskal</surname><given-names>HS</given-names></name><name><surname>Maser</surname><given-names>JD</given-names></name><name><surname>Zeller</surname><given-names>PJ</given-names></name><name><surname>Endicott</surname><given-names>J</given-names></name><name><surname>Coryell</surname><given-names>W</given-names></name><name><surname>Paulus</surname><given-names>MP</given-names></name><name><surname>Kunovac</surname><given-names>JL</given-names></name><name><surname>Leon</surname><given-names>AC</given-names></name><name><surname>Mueller</surname><given-names>TI</given-names></name><name><surname>Rice</surname><given-names>JA</given-names></name><name><surname>Keller</surname><given-names>MB</given-names></name></person-group><article-title>A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders</article-title><source>Arch Gen Psychiatry</source><year>1998</year><volume>55</volume><fpage>694</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">9707379</pub-id><pub-id pub-id-type="doi">10.1001/archpsyc.55.8.694</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name></person-group><article-title>Treating depression to remission</article-title><source>Psychiatric Annals</source><year>1995</year><volume>25</volume><fpage>704</fpage><lpage>705</lpage></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name></person-group><article-title>The clinical, psychosocial, and pharmacoeconomic ramifications of remission</article-title><source>Am J Manag Care</source><year>2001</year><volume>7</volume><fpage>S377</fpage><lpage>S385</lpage><pub-id pub-id-type="pmid">11570028</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reesal</surname><given-names>RT</given-names></name><name><surname>Lam</surname><given-names>RW</given-names></name></person-group><article-title>Clinical guidelines for the treatment of depressive disorders. II. Principles of management</article-title><source>Can J Psychiatry</source><year>2001</year><volume>46 Suppl 1</volume><fpage>21S</fpage><lpage>28S</lpage><pub-id pub-id-type="pmid">11441769</pub-id></citation></ref><ref id="B14"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>W</given-names></name></person-group><person-group person-group-type="editor"><name><surname>GuyW</surname></name></person-group><source>ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338</source><year>1976</year><publisher-name>Rockville, MD, US Department of Health, Education and Welfare</publisher-name><fpage>217</fpage><lpage>222</lpage></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>M</given-names></name><name><surname>Posternak</surname><given-names>MA</given-names></name><name><surname>Chelminski</surname><given-names>I</given-names></name></person-group><article-title>Implications of using different cut-offs on symptom severity scales to define remission from depression</article-title><source>Int Clin Psychopharmacol</source><year>2004</year><volume>19</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">15201568</pub-id><pub-id pub-id-type="doi">10.1097/01.yic.0000130232.57629.46</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Simons</surname><given-names>AD</given-names></name><name><surname>McGeary</surname><given-names>J</given-names></name><name><surname>Cahalane</surname><given-names>JF</given-names></name><name><surname>Hughes</surname><given-names>C</given-names></name><name><surname>Harden</surname><given-names>T</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name></person-group><article-title>Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment</article-title><source>Am J Psychiatry</source><year>1992</year><volume>149</volume><fpage>1046</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">1636804</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>GA</given-names></name><name><surname>Fabbri</surname><given-names>S</given-names></name><name><surname>Sonino</surname><given-names>N</given-names></name></person-group><article-title>Residual symptoms in depression: an emerging therapeutic target</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2002</year><volume>26</volume><fpage>1019</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">12452521</pub-id><pub-id pub-id-type="doi">10.1016/S0278-5846(02)00226-9</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>IW</given-names></name><name><surname>Keitner</surname><given-names>GI</given-names></name><name><surname>Schatzberg</surname><given-names>AF</given-names></name><name><surname>Klein</surname><given-names>DN</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Markowitz</surname><given-names>JC</given-names></name><name><surname>Schlager</surname><given-names>DS</given-names></name><name><surname>Kornstein</surname><given-names>SG</given-names></name><name><surname>Davis</surname><given-names>SM</given-names></name><name><surname>Harrison</surname><given-names>WM</given-names></name><name><surname>Keller</surname><given-names>MB</given-names></name></person-group><article-title>The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine</article-title><source>J Clin Psychiatry</source><year>1998</year><volume>59</volume><fpage>608</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">9862607</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><collab>American Psychiatric Association </collab></person-group><article-title>Practice guideline for the treatment of patients with major depressive disorder (revision).</article-title><source>Am J Psychiatry</source><year>2000</year><volume>157</volume><fpage>1</fpage><lpage>45</lpage></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Whybrow</surname><given-names>PC</given-names></name><name><surname>Angst</surname><given-names>J</given-names></name><name><surname>Versiani</surname><given-names>M</given-names></name><name><surname>Moller</surname><given-names>H-J</given-names></name><name><surname>Disorders</surname><given-names>WFSBP Task Force on Treatment Guidelines for Unipolar Depressive</given-names></name></person-group><article-title>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder</article-title><source>World Journal of Biological Psychiatry</source><year>2002</year><volume>3</volume><fpage>5</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12479086</pub-id></citation></ref><ref id="B21"><citation citation-type="book"><person-group person-group-type="author"><collab>Depression Guideline Panel</collab></person-group><source>Treatment of Major Depression. Clinical Practice Guideline.</source><series>Depression in Primary Care</series><year>1993</year><publisher-name>Washington, Agency for Health Care Policy and Research</publisher-name></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Entsuah</surname><given-names>AR</given-names></name><name><surname>Rudolph</surname><given-names>RL</given-names></name></person-group><article-title>Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors</article-title><source>Br J Psychiatry</source><year>2001</year><volume>178</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">11230034</pub-id><pub-id pub-id-type="doi">10.1192/bjp.178.3.234</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Dempster</surname><given-names>C</given-names></name><name><surname>Glanville</surname><given-names>J</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>I</given-names></name></person-group><article-title>Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis</article-title><source>Br J Psychiatry</source><year>2002</year><volume>180</volume><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">11983635</pub-id><pub-id pub-id-type="doi">10.1192/bjp.180.5.396</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casacalenda</surname><given-names>N</given-names></name><name><surname>Perry</surname><given-names>JC</given-names></name><name><surname>Looper</surname><given-names>K</given-names></name></person-group><article-title>Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions</article-title><source>Am J Psychiatry</source><year>2002</year><volume>159</volume><fpage>1354</fpage><lpage>1360</lpage><pub-id pub-id-type="pmid">12153828</pub-id><pub-id pub-id-type="doi">10.1176/appi.ajp.159.8.1354</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JE</given-names></name><name><surname>Barrett</surname><given-names>JA</given-names></name><name><surname>Oxman</surname><given-names>TE</given-names></name><name><surname>Gerber</surname><given-names>PD</given-names></name></person-group><article-title>The prevalence of psychiatric disorders in a primary care practice</article-title><source>Archives of General Psychiatry</source><year>1988</year><volume>45</volume><fpage>1100</fpage><lpage>1106</lpage><pub-id pub-id-type="pmid">3264145</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Schulberg</surname><given-names>H</given-names></name></person-group><article-title>Epidemiology of depression in primary care</article-title><source>Gen Hosp Psychiatry</source><year>1992</year><volume>14</volume><fpage>237</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">1505745</pub-id><pub-id pub-id-type="doi">10.1016/0163-8343(92)90094-Q</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Ward</surname><given-names>CH</given-names></name><name><surname>Mendelson</surname><given-names>M</given-names></name><name><surname>Mock</surname><given-names>J</given-names></name><name><surname>Erbaugh</surname><given-names>J</given-names></name></person-group><article-title>An inventory for measuring depression</article-title><source>Arch Gen Psychiatry</source><year>1961</year><volume>4</volume><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">13688369</pub-id></citation></ref><ref id="B28"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Collaboration</surname><given-names>Cochrane</given-names></name></person-group><source>Cochrane Manual</source><year>2004</year><publisher-name>Oxford, Cochrane Collaboration</publisher-name></citation></ref><ref id="B29"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>DM</given-names></name><name><surname>Hasselbald</surname><given-names>V</given-names></name><name><surname>Shachter</surname><given-names>R</given-names></name></person-group><source>Meta-analysis by the confidence interval method  The statistical synthesis of evidence</source><year>1992</year><publisher-name>San Diego, Academic Press Inc.</publisher-name></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuffel</surname><given-names>BJ</given-names></name><name><surname>Azocar</surname><given-names>F</given-names></name><name><surname>Tomlin</surname><given-names>M</given-names></name><name><surname>Greenfield</surname><given-names>SF</given-names></name><name><surname>Busch</surname><given-names>AB</given-names></name><name><surname>Croghan</surname><given-names>TW</given-names></name></person-group><article-title>Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice</article-title><source>J Clin Psychiatry</source><year>2003</year><volume>64</volume><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">12716239</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dowrick</surname><given-names>C</given-names></name><name><surname>Dunn</surname><given-names>G</given-names></name><name><surname>Ayuso-Mateos</surname><given-names>JL</given-names></name><name><surname>Dalgard</surname><given-names>OS</given-names></name><name><surname>Page</surname><given-names>H</given-names></name><name><surname>Lehtinen</surname><given-names>V</given-names></name><name><surname>Casey</surname><given-names>P</given-names></name><name><surname>Wilkinson</surname><given-names>C</given-names></name><name><surname>Vazquez-Barquero</surname><given-names>JL</given-names></name><name><surname>Wilkinson</surname><given-names>G</given-names></name></person-group><article-title>Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial. Outcomes of Depression International Network (ODIN) Group</article-title><source>British Medical Journal - Clinical Research</source><year>2000</year><volume>321</volume><fpage>1450</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1136/bmj.321.7274.1450</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benkert</surname><given-names>O</given-names></name><name><surname>Szegedi</surname><given-names>A</given-names></name><name><surname>Kohnen</surname><given-names>R</given-names></name></person-group><article-title>Mirtazapine compared with paroxetine in major depression</article-title><source>J Clin Psychiatry</source><year>2000</year><volume>61</volume><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">11030486</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patris</surname><given-names>M</given-names></name><name><surname>Bouchard</surname><given-names>JM</given-names></name><name><surname>Bougerol</surname><given-names>T</given-names></name><name><surname>Charbonnier</surname><given-names>JF</given-names></name><name><surname>Chevalier</surname><given-names>JF</given-names></name><name><surname>Clerc</surname><given-names>G</given-names></name><name><surname>Cyran</surname><given-names>C</given-names></name><name><surname>Van Amerongen</surname><given-names>P</given-names></name><name><surname>Lemming</surname><given-names>O</given-names></name><name><surname>Hopfner Petersen</surname><given-names>HE</given-names></name></person-group><article-title>Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice</article-title><source>Int Clin Psychopharmacol</source><year>1996</year><volume>11</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">8803650</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>A</given-names></name><name><surname>Lemming</surname><given-names>O.Michael</given-names></name><name><surname>Hedegaard</surname><given-names>K.Bang</given-names></name></person-group><article-title>Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care</article-title><source>International Clinical Psychopharmacology</source><year>2002</year><volume>17</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">11981349</pub-id><pub-id pub-id-type="doi">10.1097/00004850-200205000-00001</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chilvers</surname><given-names>C</given-names></name><name><surname>Dewey</surname><given-names>M</given-names></name><name><surname>Fielding</surname><given-names>K</given-names></name><name><surname>Gretton</surname><given-names>V</given-names></name><name><surname>Miller</surname><given-names>P</given-names></name><name><surname>Palmer</surname><given-names>B</given-names></name><name><surname>Weller</surname><given-names>D</given-names></name><name><surname>Churchill</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>I</given-names></name><name><surname>Bedi</surname><given-names>N</given-names></name><name><surname>Duggan</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Harrison</surname><given-names>G</given-names></name></person-group><article-title>Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms</article-title><source>BMJ</source><year>2001</year><volume>322</volume><fpage>772</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">11282864</pub-id><pub-id pub-id-type="doi">10.1136/bmj.322.7289.772</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mynors-Wallis</surname><given-names>LM</given-names></name><name><surname>Gath</surname><given-names>DH</given-names></name><name><surname>Lloyd-Thomas</surname><given-names>AR</given-names></name><name><surname>Tomlinson</surname><given-names>D</given-names></name></person-group><article-title>Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care</article-title><source>BMJ</source><year>1995</year><volume>310</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">7873952</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mynors-Wallis</surname><given-names>LM</given-names></name><name><surname>Gath</surname><given-names>DH</given-names></name><name><surname>Day</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>F</given-names></name></person-group><article-title>Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care.</article-title><source>BMJ</source><year>2000</year><volume>320</volume><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10617523</pub-id><pub-id pub-id-type="doi">10.1136/bmj.320.7226.26</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulberg</surname><given-names>HC</given-names></name><name><surname>Pilkonis</surname><given-names>PA</given-names></name><name><surname>Houck</surname><given-names>P</given-names></name></person-group><article-title>The severity of major depression and choice of treatment in primary care practice</article-title><source>J Consult Clin Psychol</source><year>1998</year><volume>66</volume><fpage>932</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">9874906</pub-id><pub-id pub-id-type="doi">10.1037//0022-006X.66.6.932</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>AI</given-names></name><name><surname>Freeman</surname><given-names>CP</given-names></name></person-group><article-title>Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks</article-title><source>BMJ</source><year>1992</year><volume>304</volume><fpage>883</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">1392754</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>W</given-names></name><name><surname>Von</surname><given-names>Korff M.</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Simon</surname><given-names>G</given-names></name><name><surname>Walker</surname><given-names>E</given-names></name><name><surname>Unutzer</surname><given-names>J</given-names></name><name><surname>Bush</surname><given-names>T</given-names></name><name><surname>Russo</surname><given-names>J</given-names></name><name><surname>Ludman</surname><given-names>E</given-names></name></person-group><article-title>Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial.</article-title><source>Arch Gen Psychiatry</source><year>1999</year><volume>56</volume><fpage>1109</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">10591288</pub-id><pub-id pub-id-type="doi">10.1001/archpsyc.56.12.1109</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katzelnick</surname><given-names>DJ</given-names></name><name><surname>Simon</surname><given-names>GE</given-names></name><name><surname>Pearson</surname><given-names>SD</given-names></name><name><surname>Manning</surname><given-names>WG</given-names></name><name><surname>Helstad</surname><given-names>CP</given-names></name><name><surname>Henk</surname><given-names>HJ</given-names></name><name><surname>Cole</surname><given-names>SM</given-names></name><name><surname>Lin</surname><given-names>EH</given-names></name><name><surname>Taylor</surname><given-names>LH</given-names></name><name><surname>Kobak</surname><given-names>KA</given-names></name></person-group><article-title>Randomized trial of a depression management program in high utilizers of medical care</article-title><source>Arch Fam Med</source><year>2000</year><volume>9</volume><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">10776363</pub-id><pub-id pub-id-type="doi">10.1001/archfami.9.4.345</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutcher</surname><given-names>S</given-names></name><name><surname>Leblanc</surname><given-names>J</given-names></name><name><surname>Maclaren</surname><given-names>C</given-names></name><name><surname>Hadrava</surname><given-names>V</given-names></name></person-group><article-title>A randomized trial of a specific adherence enhancement program in sertraline-treated adults with major depressive disorder in a primary care setting</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2002</year><volume>26</volume><fpage>591</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">11999913</pub-id><pub-id pub-id-type="doi">10.1016/S0278-5846(01)00313-X</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rost</surname><given-names>K</given-names></name><name><surname>Nutting</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>JL</given-names></name><name><surname>Elliott</surname><given-names>CE</given-names></name><name><surname>Dickinson</surname><given-names>M</given-names></name></person-group><article-title>Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care</article-title><source>BMJ</source><year>2002</year><volume>325</volume><fpage>934</fpage><pub-id pub-id-type="pmid">12399343</pub-id><pub-id pub-id-type="doi">10.1136/bmj.325.7370.934</pub-id></citation></ref></ref-list></back></article>



